Latest & greatest articles for pregnancy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pregnancy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pregnancy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pregnancy

1. Viral rash in pregnancy

Viral rash in pregnancy Viral rash in pregnancy - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Viral rash in pregnancy Information on the investigation, diagnosis and management of a pregnant woman who has, or is exposed to, viral rash illness. Published 1 January 2011 Last updated 22 July 2019 — From: Documents Ref: PHE publications gateway number GW-231 If you use assistive technology (...) covers rash illnesses caused by parvovirus B19 ( Telephone: 0300 123 1002 Copies of most printed publications can now be ordered online. Login to register and place your order. contains additional information. Published 1 January 2011 Last updated 22 July 2019 22 July 2019 Added new quick reference guide for health professionals. 21 March 2019 Updated 'Investigation, diagnosis and management of exposure to viral rash illness in pregnancy' document. 1 February 2016 Added link to information on Zika

2019 Public Health England

2. Urological diseases and pregnancy

Urological diseases and pregnancy DSOG 2019 Urology and pregnancy Page 1 of 3 Urological diseases and pregnancy The guideline was approved by DSOG (Danish Society of Obstetric and Gynecology) in January 2019. Members of the working group: Al-Saudi Noor, Eskildsen Morten, Fuglsang Jens, Ravn Christine, Ryhammer Allan (Urologist), Smed Vibe, Storgaard Lone Correspondence: Lone Storgaard Lone.Storgaard.01@regionh.dk Summary of clinical recommendations: Hydronephrosis Recommendation Level (...) in case of failure of other treatments. Atosiban is optional during the procedure. 3-4 D Decompression of the kidney is indicated in case of septic patient, persistent severe pain or persistent obstruction. 2b B Hematuria Recommendation Level of evidence Recommendation There is no higher risk of hypertensive disorders, preterm delivery or small for gestational age in case of idiopathic hematuria 2A-3 B DSOG 2019 Urology and pregnancy Page 2 of 3 Persistent microscopic hematuria after delivery could

2019 Nordic Federation of Societies of Obstetrics and Gynecology

3. Bacterial vaginosis in pregnancy and risk of spontaneous preterm delivery

Bacterial vaginosis in pregnancy and risk of spontaneous preterm delivery Bacterial vaginosis, proposal for the Danish guideline meeting 2015 (version 190214) Page 1 Bacterial vaginosis in pregnancy and risk of spontaneous preterm delivery Approved at the obstetrical guideline-meeting January 2015 Danish Society of Obstetrics and Gynecology (DSOG) Update February 2019 The Lancet has now published reference 31b, by Subtil et al. (2018). The 2015 version of the DSOG guideline included (...) The objective of this guideline is to evaluate bacterial vaginosis in pregnancy concerning • Different treatments for prevention of preterm delivery. • Screening of pregnant women with low as well as high risk of sPTD. • Stratification into gestational ages below and above 16 weeks. • Diagnostic methods. Key words Bacterial vaginosis, vaginal pH, pH-glove, vaginal discharge, Nugent score, Amsel score, Gardnerella vaginalis, Mobiluncus species, preterm delivery, preterm birth, GRADE, clindamycin

2019 Nordic Federation of Societies of Obstetrics and Gynecology

4. SMFM Special Statement, research to knowledge: promoting the training of physician-scientists in the biology of pregnancy

SMFM Special Statement, research to knowledge: promoting the training of physician-scientists in the biology of pregnancy Research to knowledge: promoting the training of physician-scientists in the biology of pregnancy - American Journal of Obstetrics & Gynecology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 218, Issue 1, Pages B9–B13 To read this article in full, please review your options for gaining access at the bottom of the page (...) . Research to knowledge: promoting the training of physician-scientists in the biology of pregnancy Society for Maternal-Fetal Medicine (SMFM) , x Yoel Sadovsky Affiliations Magee-Womens Research Institute, University of Pittsburgh Department of Obstetrics, Gynecology and Reproductive Sciences, Pittsburgh, Pennsylvania, USA , MD a , x Aaron B. Caughey Affiliations Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, Oregon, USA , MD, PhD b , x Michelle DiVito

2019 Society for Maternal-Fetal Medicine

5. Tobacco and pregnancy

Tobacco and pregnancy 0 Tobacco and pregnancy A national guideline from the Danish Society of Obstetrics and Gynaecology Aims • To describe the risks of adverse fetal outcomes if a pregnant woman uses tobacco products. • To describe the risks of adverse outcomes among newborn children whose mothers use tobacco products during lactation. • To suggest a strategy for screening pregnant women for use of tobacco products. • To suggest a strategy for handling women who use tobacco products during (...) pregnancy and lactation. This guideline does not deal with social aspects related to the use of tobacco products by pregnant women or their partners, and it does not deal with tobacco products as markers of use of other drugs. Recommendations Evidence level Active and passive smoking, e-cigarettes and smokeless tobacco is discouraged during pregnancy. A/B All pregnant women should be asked about smoking status, exposure to passive smoking, use of e-cigarettes and smokeless tobacco at their first contact

2019 Nordic Federation of Societies of Obstetrics and Gynecology

6. Hypertension in pregnancy: diagnosis and management

Hypertension in pregnancy: diagnosis and management Hypertension in pregnancy: diagnosis Hypertension in pregnancy: diagnosis and management and management NICE guideline Published: 25 June 2019 www.nice.org.uk/guidance/ng133 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 54Contents Contents Overview 5 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

7. Oral retinoid medicines: revised and simplified pregnancy prevention educational materials for healthcare professionals and women

Oral retinoid medicines: revised and simplified pregnancy prevention educational materials for healthcare professionals and women Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare (...) professionals and women New prescriber checklists, patient reminder cards, and pharmacy checklists are available to support the Pregnancy Prevention Programme in women taking acitretin, alitretinoin, and isotretinoin. Advice about the risk of neuropsychiatric reactions has been made consistent for all oral retinoid medicines. Published 19 June 2019 From: Therapeutic area: , , , , , Contents Advice for healthcare professionals about teratogenicity: following a detailed review, educational materials

2019 MHRA Drug Safety Update

8. Caffeine Intake During Pregnancy and Weight of Offspring in Childhood: A Systematic Review

Caffeine Intake During Pregnancy and Weight of Offspring in Childhood: A Systematic Review "Caffeine Intake During Pregnancy and Weight of Offspring in Childhood:" by Gina M. McCoy and Evelyn L. Evans < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background : Childhood obesity currently affects one third of the United States’ youth. Meeting criteria for overweight (...) is present in-utero . The current review explores the relationship between caffeine consumption during pregnancy and the weight of offspring in childhood. The purpose of this review is to organize and critically appraise the current data in order to realign our standard of care with the most recent information. Preventing childhood obesity is our best line of defense for our children and the health of our nation. Method : A comprehensive search of MEDLINE-PubMed, Web of Science, CINAHL-EBSCO, and MEDLINE

2019 Pacific University EBM Capstone Project

9. Pregnancy and early life: reducing stillbirth and infant death

Pregnancy and early life: reducing stillbirth and infant death Pregnancy and early life: reducing stillbirth and infant death - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Pregnancy and early life: reducing stillbirth and infant death A planning tool to examine factors that influence stillbirth and infant death at the population level, rather than in individual clinical care. Published 12 March 2019

2019 Public Health England

10. Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy

Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy Do Doxylamine/p xylamine/pyrido yridoxine (X xine (Xon onv vea) for treating ea) for treating nausea and v nausea and vomiting of pregnancy omiting of pregnancy Evidence summary Published: 24 June 2019 www.nice.org.uk/guidance/es20 pathways K Ke ey messages y messages The content of this evidence review was up-to-date in April 2019. See summaries of product characteristics (SPCs), British national formulary (BNF (...) ) or the Medicines and Healthcare products Regulatory Agency (MHRA) or NICE websites for up-to-date information. Xonvea (Alliance Pharmaceuticals) is a delayed-release tablet containing doxylamine succinate 10 mg (an antihistamine) and pyridoxine hydrochloride 10 mg (vitamin B6). In July 2018, it was granted a marketing authorisation for treating nausea and vomiting of pregnancy in women (aged 18 years or older) who do not respond to conservative management. Doxylamine/pyridoxine is taken every day

2019 National Institute for Health and Clinical Excellence - Advice

11. Critical Care in Pregnancy

Critical Care in Pregnancy Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

12. Pregnancy and Heart Disease

Pregnancy and Heart Disease Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2019 American College of Obstetricians and Gynecologists

13. Viral rash in pregnancy

Viral rash in pregnancy Guidance on the investigation, diagnosis and management of viral illness, or exposure to viral rash illness, in pregnancy Guidance on the investigation, diagnosis and management of viral rash illness, or exposure to viral rash illness, in pregnancy 2 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence (...) : @PHE_uk Facebook: www.facebook.com/PublicHealthEngland Prepared by: Nalini Iyanger, Helen Campbell, Gayatri Amirthalingam and Kevin Brown. For queries relating to this document, please contact: Immunisation.lead@phe.gov.uk Telephone: 0208 200 4000. Acknowledgements: The authors gratefully acknowledge the expert review and advice received from: ? The NHS Infectious Diseases in Pregnancy Screening (IDPS) Screening Midwives and Specialist Nurses forum ? Royal College of Obstetricians and Gynaecologists

2019 Public Health England

14. Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects

Methylphenidate (Ritalin and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Prescrire IN ENGLISH - Spotlight ''Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects'', 1 June 2019 {1} {1} {1} | | > > > Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Methylphenidate (Ritalin° and other brands) during pregnancy: teratogenic and fetotoxic, with concerns about long-term effects FEATURED REVIEW Methylphenidate is an amphetamine-like psychostimulant used in attention deficit hyperactivity disorder (ADHD). Recent studies have revealed important data about the consequences of in utero exposure

2019 Prescrire

15. Cerclage for women with twin pregnancies: a systematic review and meta-analysis

Cerclage for women with twin pregnancies: a systematic review and meta-analysis This study was conducted to estimate whether cerclage could extend the prolongation of pregnancy, reduce the risk of preterm birth, and improve perinatal outcomes in women with twin pregnancies.We included randomized controlled trials and cohort studies comparing the efficacy of cerclage with no cerclage for women with twin pregnancies.The following databases were searched for all published studies that compared (...) cerclage placement with expectant management in twin pregnancies from inception to July 2018: Medline, EMBASE, Scopus, ClinicalTrials.gov, Web of Science, and Cochrane Library. Each report was reviewed for inclusion or exclusion standard, and data extraction was performed by 2 authors independently.A total of 16 studies with 1211 women that met the inclusion criteria were included in the final analysis. Our outcomes indicated that cerclage placement for twin pregnancies with a cervical length of <15 mm

2019 EvidenceUpdates

16. Management of Preexisting Diabetes in Pregnancy: A Review. (PubMed)

Management of Preexisting Diabetes in Pregnancy: A Review. The presence of preexisting type 1 or type 2 diabetes in pregnancy increases the risk of adverse maternal and neonatal outcomes, such as preeclampsia, cesarean delivery, preterm delivery, macrosomia, and congenital defects. Approximately 0.9% of the 4 million births in the United States annually are complicated by preexisting diabetes.Women with diabetes have increased risk for adverse maternal and neonatal outcomes, and similar risks (...) are present with type 1 and type 2 diabetes. Both forms of diabetes require similar intensity of diabetes care. Preconception planning is very important to avoid unintended pregnancies and to minimize risk of congenital defects. Hemoglobin A1c goals are less than 6.5% at conception and less than 6.0% during pregnancy. It is also critical to screen for and manage comorbid illnesses, such as retinopathy and nephropathy. Medications known to be unsafe in pregnancy, such as angiotensin-converting enzyme

2019 JAMA

17. A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. (PubMed)

A Randomized Trial of Progesterone in Women with Bleeding in Early Pregnancy. Bleeding in early pregnancy is strongly associated with pregnancy loss. Progesterone is essential for the maintenance of pregnancy. Several small trials have suggested that progesterone therapy may improve pregnancy outcomes in women who have bleeding in early pregnancy.We conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate progesterone, as compared with placebo, in women (...) with vaginal bleeding in early pregnancy. Women were randomly assigned to receive vaginal suppositories containing either 400 mg of progesterone or matching placebo twice daily, from the time at which they presented with bleeding through 16 weeks of gestation. The primary outcome was the birth of a live-born baby after at least 34 weeks of gestation. The primary analysis was performed in all participants for whom data on the primary outcome were available. A sensitivity analysis of the primary outcome

2019 NEJM

18. Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy

Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Magnesium sulfate: risk of skeletal adverse effects in the neonate following prolonged or repeated use in pregnancy Maternal administration of magnesium sulfate for longer than 5–7 days in pregnancy has (...) been associated with skeletal adverse effects and hypocalcaemia and hypermagnesemia in neonates. If use of magnesium sulfate in pregnancy is prolonged or repeated, consider monitoring of neonates for abnormal calcium and magnesium levels and skeletal adverse effects. Published 17 May 2019 From: Therapeutic area: , , , Contents Advice for healthcare professionals: maternal administration of magnesium sulfate for longer than 5–7 days in pregnancy may be associated with adverse effects in the foetus

2019 MHRA Drug Safety Update

19. BHIVA guidelines on the management of HIV in pregnancy and postpartum

BHIVA guidelines on the management of HIV in pregnancy and postpartum British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018 BHIVA guidelines on the management of HIV in pregnancy and postpartum 2 Guideline writing group Dr Yvonne Gilleece (Chair) Honorary Clinical Senior Lecturer and Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust Dr Shema Tariq (Vice-chair) Postdoctoral Clinical Research Fellow (...) of Leicester NHS Trust Dr Luciana Rubinstein Consultant in Genitourinary Medicine, London North West Healthcare University NHS Trust, London Ms Sonali Sonecha Lead Directorate Pharmacist HIV/GUM, Chelsea and Westminster Healthcare NHS Foundation Trust, London Dr Lisa Thorley UK Community Advisory Board representative Dr Pat Tookey Honorary Senior Lecturer and Co-Investigator National Study of HIV in Pregnancy and Childhood, UCL Great Ormond Street Institute of Child Health, London Ms Jennifer Tosswill

2019 British HIV Association

20. Doxylamine succinate and pyridoxine hydrochloride (Xonvea) for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management

Doxylamine succinate and pyridoxine hydrochloride (Xonvea) for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management 1 Published 13 May 2019 1 SMC2140 doxylamine succinate 10mg and pyridoxine hydrochloride 10mg gastro-resistant tablets (Xonvea®) Alliance Pharmaceuticals Limited 5 April 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (...) (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission doxylamine succinate and pyridoxine hydrochloride (Xonvea®) is not recommended for use within NHSScotland. Indication under review: the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Doxylamine in combination with pyridoxine significantly improved symptoms of nausea and vomiting compared with placebo in women with nausea and vomiting

2019 Scottish Medicines Consortium